Cann Group Limited (ASX: CAN)
Cann Group Limited (ASX: CAN) is involved in the operations of providing medicinal cannabis products for patients in Australia and globally. Recently, in the September quarter, the company achieved a significant milestone in its plans of becoming a fully integrated medicinal cannabis company by supplying the first Australian patients with Aurora cannabis oil through the Therapeutic Good Administration’s (TGA) Special Access Scheme. Further, the company is also going to be the partner in Australia’s first research hub for medicinal agriculture at La Trobe University which is in Melbourne. During the September quarter, the company also entered into a manufacturing agreement with IDT Australia for the production of medicinal cannabis? based product formulations.
In the last six months, the share price of the company decreased by 26.45 percent as on 5 December 2018. CAN’s shares traded at $2.180 with a market capitalization of circa $318.28 million as on 6 December 2018 (AEST 4:00 PM).
Elixinol Global Limited (ASX: EXL)
Elixinol Global Limited (ASX: EXL) is a manufacturer of medicinal cannabis products and is having a global presence in the cannabis industry. In the month of November 2018, the company announced that is increasing its ownership to 50.5 percent in a newly restructured Japanese hemp-derived cannabidiol (CBD), hemp foods and skincare business. At the end of the September quarter, the Company was having a pro forma cash balance of A$48.6 million which comprised of A$10.7 million worth of cash at bank and net proceeds of A$37.9 million that were received from the capital raising on 3 October 2018. During the September quarter of 2018, the company’s revenue grew by 27% to $10.4 million as compared to 2Q quarter of FY18.
In the last six months, the share price of the company increased by 28.12% as on 5 December 2018. EXL’s shares traded at $1.865 (-9.024% intraday) with a market capitalization of circa $255.33 million as on 6 December 2018 (AEST 4:00 PM).
Medlab Clinical Limited (ASX: MDC)
Medlab Clinical Limited (ASX: MDC) is involved in the development of Cannabis Drugs and further it also develops bacteria-based medicines, based on the human microbiome. Medlab has a dedicated team of Sales Representatives who engage with Pharmacy and GPs in Australia providing training and merchandising support to the Pharmacy. Medlab’s products are currently sold in more than 600 pharmacies in Australia. Recently, the company was granted an export license as export opportunities are continuing to increase.
In FY 2018, the revenue from ordinary activities increased by 25 percent as compared to the previous year. In Q1 2018, the revenues increased by 24 percent as compared to the corresponding previous period. As at 30 September 2018, the company was having the cash balance of $18.4 million.
In the last six months, the share price of Medlab decreased by 15.79 percent as on 5 December 2018. The company’s share last traded at $0.400 with a market capitalization of circa $83.21 million as on 6 December 2018.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.